Arvinas, Inc. (ARVN)
9.60
+0.26
(+2.78%)
USD |
NASDAQ |
Aug 25, 16:00
9.60
0.00 (0.00%)
Pre-Market: 19:59
Arvinas Total Liabilities (Quarterly) : 112.90M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 112.90M |
| March 31, 2026 | 260.70M |
| December 31, 2025 | 284.00M |
| September 30, 2025 | 279.90M |
| June 30, 2025 | 300.00M |
| March 31, 2025 | 341.00M |
| December 31, 2024 | 529.70M |
| September 30, 2024 | 581.10M |
| June 30, 2024 | 679.40M |
| March 31, 2024 | 602.90M |
| December 31, 2023 | 644.60M |
| September 30, 2023 | 601.10M |
| June 30, 2023 | 619.90M |
| March 31, 2023 | 664.80M |
| December 31, 2022 | 703.90M |
| September 30, 2022 | 713.30M |
| June 30, 2022 | 736.40M |
| March 31, 2022 | 765.00M |
| Date | Value |
|---|---|
| December 31, 2021 | 804.90M |
| September 30, 2021 | 787.13M |
| June 30, 2021 | 61.08M |
| March 31, 2021 | 66.47M |
| December 31, 2020 | 77.53M |
| September 30, 2020 | 66.83M |
| June 30, 2020 | 64.80M |
| March 31, 2020 | 70.74M |
| December 31, 2019 | 76.28M |
| September 30, 2019 | 74.93M |
| June 30, 2019 | 55.54M |
| March 31, 2019 | 58.83M |
| December 31, 2018 | 62.61M |
| September 30, 2018 | 62.56M |
| June 30, 2018 | 61.71M |
| March 31, 2018 | 65.09M |
| December 31, 2017 | 66.60M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Cocrystal Pharma, Inc. | 3.605M |
| CNBX Pharmaceuticals, Inc. | 2.672M |
| GB Sciences, Inc. | -- |
| Fulcrum Therapeutics, Inc. | 13.26M |
| Definium Therapeutics, Inc. | 194.22M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 675.10M |
| Shareholders Equity (Quarterly) | 562.20M |
| Debt to Equity Ratio | 0.0146 |
| Current Ratio | 7.906 |
| Net Debt Paydown Yield | 0.09% |